Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: MYGN

Myriad Genetics, Inc.

Healthcare | Medical - Diagnostics & Research

No licensed closing price on file for MYGN. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (FY2025)$-3.95

Myriad Genetics, Inc. (NASDAQ: MYGN) is a diagnostics and research company. Figures from SEC EDGAR; updated 2026-10-21 15:24 UTC.

What Myriad Genetics, Inc. does

Myriad Genetics develops and commercializes molecular tests that analyze genes to assess disease risk, guide treatment decisions, and detect disease progression across oncology, women's health, and mental health. The company's strategy focuses on expanding its Cancer Care Continuum testing portfolio, growing prenatal and mental health revenues, and achieving profitability through operational discipline and technology-enabled capabilities. The company recently completed a transition to next-generation laboratory facilities designed to enhance automation and reduce costs.

Summarized from Myriad Genetics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (FY2025)$-3.95
Debt/equity0.40

Revenue, margins & earnings

FY2021: net loss $27M on revenue $691M$691MFY2021FY2022: net loss $112M on revenue $678M$678MFY2022FY2023: net loss $263M on revenue $753M$753MFY2023FY2024: net loss $127M on revenue $838M$838MFY2024FY2025: net loss $366M on revenue $824M$824MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-22
  • 2026-09-22Chief Financial OfficerTax withholding-2,555$10.2K
  • 2026-09-17EVP, CommercialAward257,731—
  • 2026-09-08Chief Legal OfficerTax withholding-4,398$14.2K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Myriad Genetics, Inc. do?

Myriad Genetics develops and commercializes molecular tests that analyze genes to assess disease risk, guide treatment decisions, and detect disease progression across oncology, women's health, and mental health.

When did MYGN last file with the SEC?

Myriad Genetics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-23. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-21 15:24 UTC. This page is also available as JSON at /api/data?ticker=MYGN and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for MYGN and 5,000+ tickers.

Create a free account — keep MYGN
For your agent
GET /api/data?ticker=MYGN

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt